Related Experiment Video

Updated: Apr 18, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Novel angiogenesis inhibitors in nonsmall cell lung cancer

Niels Reinmuth1, David Heigener, Martin Reck

  • 1aDepartment of Thoracic Oncology, LungenClinic Großhansdorf, Grosshansdorf bAirway Research Center North, German Center for Lung Research (DZL), Heidelberg, Germany.

Current Opinion in Oncology
|January 21, 2015
PubMed
Abstract

Insights

Antiangiogenic agents, like bevacizumab, are showing promise in treating advanced non-small cell lung cancer (NSCLC). Recent trials highlight their efficacy when combined with chemotherapy, offering new therapeutic avenues for lung cancer patients.

Area of Science:

  • Oncology
  • Cancer Research
  • Thoracic Oncology

Background:

  • Tumor growth and spread are angiogenesis-dependent.
  • Antiangiogenic agents are being investigated for thoracic tumors, including non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To review and evaluate recent developments in antiangiogenic therapy for thoracic tumors.
  • To assess the role of antiangiogenic agents in non-small cell lung cancer treatment strategies.

Main Methods:

  • Review of recent clinical trials and therapeutic strategies.
  • Evaluation of antiangiogenic agents in combination with chemotherapy and docetaxel.

Main Results:

  • Bevacizumab, an anti-vascular endothelial growth factor antibody, is approved for advanced NSCLC (nonsquamous histology) with platinum-based chemotherapy.
  • Antiangiogenic therapy in NSCLC involves maintenance treatment until disease progression.
  • Recent trials demonstrate efficacy of antiangiogenic agents combined with docetaxel in the second-line setting.

Conclusions:

  • Antiangiogenic treatment strategies have shown renewed promise in lung cancer.
  • Experiences from other cancer types support the application of antiangiogenic therapy in NSCLC.
  • Further research and clinical trials are ongoing to optimize antiangiogenic approaches for lung cancer.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
580
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.9K